Status:
COMPLETED
Intratumoral Heterogeneity on [18F]PSMA and [18F]FDG PET/CT in Predicting Invasion and Prognosis of Prostate Cancer
Lead Sponsor:
Jiequn Yu
Conditions:
Prostate Cancer (Diagnosis)
Prostate-specific Membrane Antigen
Eligibility:
MALE
18+ years
Brief Summary
The purpose of this study is to analyze heterogeneity of prostate cancer（PCa）based on the head-to-head imaging of prostate-specific membrane antigen (PSMA) and fluorodeoxyglucose (FDG) positron emissi...
Detailed Description
PET/CT examinations were performed on different days using Siemens Biograph MCT PET/CT equipment. All patients were examined on the same scanner. Patients were fasted for more than 6 h before \[18F\]F...
Eligibility Criteria
Inclusion
- Untreated patients with PCa confirmed by prostate systemic pathological biopsy
- Patients underwent \[18F\]PSMA-1007 and \[18F\]FDG PET/CT and the imaging interval was less than one month.
Exclusion
- Patients received treatment at intervals of two imaging
- Imaging was less than 1 week after pathology biopsy
Key Trial Info
Start Date :
July 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 30 2022
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT06919159
Start Date
July 1 2021
End Date
November 30 2022
Last Update
April 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Nuclear Medicine, The First Hospital of China Medical University
Shenyang, Liaoning, China, 110001